<SEC-DOCUMENT>0001739410-24-000053.txt : 20240509
<SEC-HEADER>0001739410-24-000053.hdr.sgml : 20240509
<ACCEPTANCE-DATETIME>20240509081147
ACCESSION NUMBER:		0001739410-24-000053
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20240509
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240509
DATE AS OF CHANGE:		20240509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Rallybio Corp
		CENTRAL INDEX KEY:			0001739410
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				851083789
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40693
		FILM NUMBER:		24928709

	BUSINESS ADDRESS:	
		STREET 1:		234 CHURCH STREET
		STREET 2:		SUITE 1020
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06510
		BUSINESS PHONE:		203- 859-3820

	MAIL ADDRESS:	
		STREET 1:		234 CHURCH STREET
		STREET 2:		SUITE 1020
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06510

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Rallybio Holdings, LLC
		DATE OF NAME CHANGE:	20180502
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>rlyb-20240509.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:628142cb-3778-46d6-9162-2ee6661fc53b,g:aa3b354b-9fb2-407d-ba15-42096dce7890,d:485d710d5e914ce8a7c330aac1766c0e-->
<html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>rlyb-20240509</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-23">0001739410</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-24">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="rlyb-20240509.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739410</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-09</xbrli:startDate><xbrli:endDate>2024-05-09</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i485d710d5e914ce8a7c330aac1766c0e_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________________________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________________________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">May 09, 2024</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">RALLYBIO CORPORATION</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(Exact name of Registrant as Specified in Its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________________________</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-40693</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">85-1083789</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(State or Other Jurisdiction<br/>of Incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(IRS Employer<br/>Identification No.)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">234 Church Street,</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-8">Suite 1020</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">New Haven,</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-10">Connecticut</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">06510</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s Telephone Number, Including Area Code:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">203</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">859-3820</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.678%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-14">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-15">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-16">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-17">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.658%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading<br/>Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-18">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-19">RLYB</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-20">NASDAQ Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="f-21">x</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="f-22">o</ix:nonNumeric></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i485d710d5e914ce8a7c330aac1766c0e_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02 Results of Operations and Financial Condition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 9, 2024, Rallybio Corporation issued a press release announcing its financial results for the quarter ended March 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information contained in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></div><div id="i485d710d5e914ce8a7c330aac1766c0e_10"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01 Financial Statements and Exhibits.</span></div><div style="margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.84pt">Exhibits</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.173%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="rlyb-20240509xex991pressre.htm">Press release issued by the Company on May 9, 2024 regarding financial results for the fiscal quarter ended March 31, 2024</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i485d710d5e914ce8a7c330aac1766c0e_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RALLYBIO CORPORATION</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Jonathan I. Lieber</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jonathan I. Lieber<br/>Chief Financial Officer and Treasurer</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>rlyb-20240509xex991pressre.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i739147c85d95481ea9a7d37c2b5df027_1"></div><div style="min-height:45pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Exhibit 99.1</font></div></div><div style="margin-top:12pt;text-align:center"><img alt="img96626370_0.jpg" src="img96626370_0.jpg" style="height:45px;margin-bottom:5pt;vertical-align:text-bottom;width:158px"></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:107%">Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">&#822;  On Track to Initiate RLYB212 Phase 2 Dose Confirmation Trial in Pregnant Women at Higher Risk of FNAIT in 2H 2024  &#822; </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">&#822;  $94.2 Million in Cash, Cash Equivalents, and Marketable Securities as of March 31, 2024&#59; Provides Runway into Mid-2026  &#822; </font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">NEW HAVEN, Conn., May 9, 2024 -- </font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Rallybio Corporation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%"> (Nasdaq&#58; RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported first quarter financial results for the period ended March 31, 2024 and provided an update on recent company developments. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;This year is off to a strong start as we continue to progress towards the initiation of our Phase 2 dose confirmation trial for RLYB212 in pregnant women at higher risk of FNAIT, which is on track for the second half of 2024,&#34; said Stephen Uden, M.D., Chief Executive Officer of Rallybio. &#34;Last month, we were particularly pleased to announce our collaboration with Johnson &#38; Johnson, marking a significant step forward in our mission to eliminate FNAIT and its devastating consequences. Together with Johnson &#38; Johnson, we look forward to further driving awareness of FNAIT, emphasizing the importance of screening for FNAIT risk, and advancing our complementary therapeutic approaches, which aim to ensure all pregnant women at risk of FNAIT have a potential treatment option regardless of their alloimmunization status.&#34; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Dr. Uden continued, &#34;In the near-term, we look forward to sharing initial data from an epidemiologic analysis investigating the genetic markers of FNAIT risk in a racially and ethnically diverse population beyond the Caucasian population, where FNAIT risk has been better established in published literature. This analysis will more accurately inform the number of pregnant women at higher risk for FNAIT annually. We expect that these data combined with data from our ongoing FNAIT natural history study will further emphasize the need for a preventative therapeutic and identify a market opportunity for RLYB212 that is larger than our current estimates.&#34;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:107%;text-decoration:underline">Recent Business Highlights and Upcoming Milestones&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:107%">Corporate Updates</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:14.15pt">In April 2024, Rallybio announced a collaboration with Momenta Pharmaceuticals, Inc., a Johnson &#38; Johnson Company, to advance complementary therapeutic solutions for pregnant women at risk of fetal and neonatal alloimmune thrombocytopenia (FNAIT). Rallybio received an equity investment of $6.6 million from Johnson &#38; Johnson Innovation &#8211; JJDC, Inc. </font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">In February 2024, Rallybio announced a prioritization of its portfolio and a 45% workforce reduction to focus the Company&#8217;s resources on its two Phase 2 ready assets, RLYB212, a novel human monoclonal anti-HPA-1a antibody in development for the prevention of FNAIT, and RLYB116, a once-weekly, low volume subcutaneously injected inhibitor of complement component 5 (C5) in development for patients with complement-mediated diseases. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:107%">RLYB212 Program</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:14.15pt">Rallybio is on track to initiate a Phase 2 trial in pregnant women at higher risk for HPA-1a alloimmunization and FNAIT in the second half of 2024. The primary objectives of this trial are to assess the pharmacokinetics and safety of subcutaneously administered RLYB212 in pregnant women. Secondary objectives include assessments of pregnancy and neonatal outcomes, and the occurrence of emergent HPA-1a alloimmunization. Administration of RLYB212 will be initiated by Gestational Week 16 and continue every 4 weeks through parturition.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:14.15pt">Screening in the Company's FNAIT natural history study is ongoing. This study is designed to provide a contemporary dataset for HPA-1a alloimmunization frequency in a racially and ethnically diverse population. As of May 1, 2024, Rallybio has screened approximately 10,000 pregnant women. The FNAIT natural history study is designed to run in parallel with the Phase 2 study and to continue through to initiation of the planned Phase 3 trial to enable seamless transition of participating sites into the registration trial.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:14.15pt">To better understand the frequency of HPA-1a-negative, HLA-DRB3*01&#58;01-positive status in a broad and diverse population, Rallybio partnered with HealthLumen, a leader in epidemiological modeling of rare genetic diseases, to conduct an epidemiologic analysis utilizing information from large genomic datasets. Rallybio expects data from this analysis to be disclosed in mid-2024.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">Several presentations and publications are expected in the second half of 2024, including additional data from the Phase 1b proof-of-concept study and an integrated summary of clinical and nonclinical data supporting the RLYB212 Phase 2 dose.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:107%">RLYB116 Program</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:14.15pt">RLYB116 manufacturing work continues and is on track to complete in the second half of 2024. Furthermore, additional biomarker development work is underway to further evaluate results of the Phase 1 multiple ascending dose (MAD) study, which was completed in the fourth quarter of 2023. Rallybio expects to provide an update on this analysis and future development plans for RLYB116 in the second half of 2024.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:105%">Preclinical Programs</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Rallybio continues to believe that its preclinical programs have the potential to address significant existing unmet needs for patients and caregivers and bring meaningful value to stakeholders. Given Rallybio's focus of current capital and resources on its clinical-stage assets, primarily RLYB212, the Company is seeking alternative options to further advance its preclinical programs, including partnerships and other forms of non-dilutive financing.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:105%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:105%;padding-left:14.15pt">RLYB332&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:105%"> In the first quarter of 2024, Rallybio completed nonclinical studies that demonstrated favorable tolerability, dose-dependent pharmacokinetics, and sustained pharmacodynamic effects with RLYB332, a long-acting version of the RLYB331 anti-Matriptase-2 antibody. These findings support the continued development of RLYB332 as a potentially best-in-class therapeutic for treating diseases of iron overload. Presentation of this data is expected in the second half of 2024.  </font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:14.15pt">RLYB114, EyePoint Collaboration&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> EyePoint has demonstrated feasibility for sustained delivery of Rallybio&#8217;s inhibitor of C5 using EyePoint&#8217;s proprietary intraocular drug delivery technology, and optimization work is ongoing.</font></div><div><font style="color:#ff0000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%"> </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:107%">First Quarter 2024 Financial Results </font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:14.15pt">Research &#38; Development (R&#38;D) Expenses&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">R&#38;D expenses were $12.9 million for the first quarter of 2024, compared to $11.2 million for the same period in 2023. The increase in R&#38;D expense was primarily due to an increase in payroll and personnel-related costs, largely related to severance costs incurred in connection with the workforce reduction, effective March 6, 2024. The increase was partially offset by a decrease in costs related to the development of RLYB212.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:14.15pt">General &#38; Administrative (G&#38;A) Expenses&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> G&#38;A expenses were $6.9 million for the first quarter of 2024, compared to $7.2 million for the same period in 2023. The decrease in G&#38;A expense was primarily related to decreases in other general and administrative related expenses and director and officer insurance premiums. This decrease was partially offset by an increase in payroll and personnel-related costs, primarily related to severance costs incurred in connection with the workforce reduction, effective March 6, 2024.</font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:14.15pt">Net Loss and Net Loss Per Common Share&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Rallybio reported a net loss of $19.0 million, or $0.47 per common share, for the first quarter of 2024. This compares to a net loss of $17.3 million, or $0.43 per common share, for the first quarter of 2023.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:14.15pt">Cash Position&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> As of March 31, 2024, cash, cash equivalents, and marketable securities were $94.2 million. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Rallybio</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Rallybio (NASDAQ&#58; RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Rallybio has built a broad pipeline of promising product candidates aimed at addressing diseases with unmet medical need in areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. The Company has two clinical stage programs&#58; RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development. Rallybio is headquartered in New Haven, Connecticut. For more information, please visit </font><font style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">www.rallybio.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and follow us on </font><font style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">LinkedIn</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Twitter</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This press release contains forward-looking statements that are based on our management&#8217;s beliefs and assumptions and on currently available information. All statements, other than statements of historical facts contained in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements concerning the timing of initiation of the Phase 2 dose confirmation study for RLYB212, the release of screening numbers of women in the natural history study, whether the results of the natural history study and the planned Phase 2 dose confirmation study will be sufficient to support design and implementation of a Phase 3 registrational study for RLYB212, whether the manufacturing work for RLYB116 will be timely completed or successful, the timing of the availability of data from our clinical studies, our expectations regarding the usefulness of data from our clinical studies, our expectations regarding driving awareness of FNAIT through the Johnson &#38; Johnson collaboration, our ability to more accurately identify the number of pregnant women at higher risk of FNAIT based on the results of the genomic analysis, our estimates of the market opportunity for RLYB212, the timing of publications relating to FNAIT and RLYB212, the timing of completion of the RLYB116 biomarker work, the timing of achieving milestones in 2024 for our preclinical programs, the likelihood that Rallybio will be successful in developing RLYB212, RLYB116, or any of our other product candidates, our ability to successfully identify and implement alternative and acceptable options to further advance our programs, our estimates of our capital requirements and the sufficiency thereof, and our cash runway. The forward-looking statements in this press release are only predictions and are based largely on management&#8217;s current expectations and projections about future events and financial trends that management believes may affect Rallybio&#8217;s business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions, including, but not limited to, our ability to successfully initiate and conduct our planned clinical trials, including the FNAIT natural history study, and the Phase 2 clinical trial for RLYB212, and complete such clinical trials and obtain results on our expected timelines, or at all, whether our cash resources will be sufficient to fund our operating expenses and capital expenditure requirements and whether we will be successful raising additional capital, our ability to enter into strategic partnerships or other arrangements, competition from other biotechnology and pharmaceutical companies, and those risks and uncertainties described in Rallybio&#8217;s filings with the </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S. Securities and Exchange Commission (SEC), including Rallybio&#8217;s Annual Report on Form 10-K for the period ended December 31, 2023, and subsequent filings with the SEC. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual future results, levels of activity, performance and events and circumstances could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we are not obligated to publicly update or revise any forward-looking statements contained in this press release, whether as a result of any new information, future events, changed circumstances or otherwise.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i739147c85d95481ea9a7d37c2b5df027_4"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Financial Tables</font></div><div id="i739147c85d95481ea9a7d37c2b5df027_7"></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RALLYBIO CORPORATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SELECTED CONDENSED CONSOLIDATED FINANCIAL INFORMATION</font></div><div id="i739147c85d95481ea9a7d37c2b5df027_10"></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.143%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FOR THE THREE MONTHS ENDED MARCH 31,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except share and per share amounts)</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,936&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,202&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,851&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,172&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,787&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,374&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,787)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,374)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,276&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,546&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income, net</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,443&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,619&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before equity in losses of joint venture</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,344)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,755)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on investment in joint venture</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">685&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,029)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,318)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share, basic and diluted</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.47)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.43)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic and diluted</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,773,615</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,248,893</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) gain&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized (loss) gain on marketable securities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) gain</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,115)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,165)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div id="i739147c85d95481ea9a7d37c2b5df027_13"></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:68.854%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.315%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.925%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">MARCH 31,<br>2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DECEMBER 31,<br>2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and marketable securities</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,175&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,929&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,359</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,620</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,202</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,436</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,157</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,184</font></td></tr></table></div><div id="i739147c85d95481ea9a7d37c2b5df027_16"></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Contacts</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Investors</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Samantha Tracy</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Rallybio Corporation</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(475) 47-RALLY (Ext. 282)</font></div><div><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">investors&#64;rallybio.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Kevin Lui</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Stern Investor Relations, Inc.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(760) 579-2134</font></div><div><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Kevin.Lui&#64;sternir.com</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Media</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Victoria Reynolds</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Mission North</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(760) 579-2134</font></div><div><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">rallybio&#64;missionnorth.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%"><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>rlyb-20240509.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:628142cb-3778-46d6-9162-2ee6661fc53b,g:aa3b354b-9fb2-407d-ba15-42096dce7890-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:rlyb="http://rallybio.com/20240509" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://rallybio.com/20240509">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rlyb-20240509_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rlyb-20240509_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://rallybio.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>rlyb-20240509_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:628142cb-3778-46d6-9162-2ee6661fc53b,g:aa3b354b-9fb2-407d-ba15-42096dce7890-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_f9db9882-ed67-4a59-aab8-d0f1f6279c96_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_2aec92a3-75a0-4e61-9de3-ece9c823f02a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_14b37ad0-bb58-46df-a794-b7efc583cb96_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_7a590dec-1684-41bb-bbb6-2fd65bcada16_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_7ab2cca9-d14c-498d-9fb6-565e156dbd5c_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_48a3689d-a967-43d9-9864-a8c2543d7b2c_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_10eead44-ee4f-43d7-9299-f1956983def6_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_6abe3a2e-51bb-4b39-b6de-98f9a1bd916b_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_add78e29-2071-4ff2-bc68-051ae770d82e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_19e16045-0a09-4ddb-bb9c-bf0bd0403bcb_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_e701b583-13d7-45fd-9942-e93dc5944a5d_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_a9ae99e8-904c-4900-81b7-fecefa2a3048_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_4a10f00e-e6b6-4120-a737-83126eafe230_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_e5d40501-cff1-4802-a273-728aa70119a3_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_5031ae73-e660-4f14-a52e-8e349c3e6606_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_4997131a-cc2a-48d9-bd1c-fa431f496708_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_58fcea35-1b64-40b5-82cd-be91da8228a4_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_469fa2a3-db3e-4f78-9464-a9b5c658d4cf_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_02a484ad-2ce3-4646-8f90-1c87afaea2f3_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_5e020d57-a066-4ae1-a26b-8a7e3482ae60_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_1cc7fa5a-e1d6-45d2-8f49-a46b8ce9b3dd_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_9564b8d6-8753-4ecd-b9e3-b0de1485c170_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_b7967da3-e891-42fd-af99-221f77499d96_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_90b49dd8-b6d5-4359-8cd3-c5a86100ad70_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>rlyb-20240509_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:628142cb-3778-46d6-9162-2ee6661fc53b,g:aa3b354b-9fb2-407d-ba15-42096dce7890-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://rallybio.com/role/Cover" xlink:type="simple" xlink:href="rlyb-20240509.xsd#Cover"/>
  <link:presentationLink xlink:role="http://rallybio.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_3789ce0d-00ad-45ee-be67-9f8cff63fe46" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_c88501f6-690c-499b-8c43-feb01de37bb7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3789ce0d-00ad-45ee-be67-9f8cff63fe46" xlink:to="loc_dei_DocumentType_c88501f6-690c-499b-8c43-feb01de37bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_b18f3072-9559-4c6b-824b-4aee6c87039c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3789ce0d-00ad-45ee-be67-9f8cff63fe46" xlink:to="loc_dei_DocumentPeriodEndDate_b18f3072-9559-4c6b-824b-4aee6c87039c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_d5911844-1303-404d-8ea8-ba0079e895d2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3789ce0d-00ad-45ee-be67-9f8cff63fe46" xlink:to="loc_dei_EntityRegistrantName_d5911844-1303-404d-8ea8-ba0079e895d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_4a33d434-cda7-4b5f-ab08-fe065664b434" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3789ce0d-00ad-45ee-be67-9f8cff63fe46" xlink:to="loc_dei_EntityIncorporationStateCountryCode_4a33d434-cda7-4b5f-ab08-fe065664b434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_1dde699a-6592-4a0c-949d-6721116c635f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3789ce0d-00ad-45ee-be67-9f8cff63fe46" xlink:to="loc_dei_EntityFileNumber_1dde699a-6592-4a0c-949d-6721116c635f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_7e4a7126-dae4-4e57-91e3-7c9b952712fe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3789ce0d-00ad-45ee-be67-9f8cff63fe46" xlink:to="loc_dei_EntityTaxIdentificationNumber_7e4a7126-dae4-4e57-91e3-7c9b952712fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_2cb15e66-46cb-48bc-a19b-755c8cc330f4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3789ce0d-00ad-45ee-be67-9f8cff63fe46" xlink:to="loc_dei_EntityAddressAddressLine1_2cb15e66-46cb-48bc-a19b-755c8cc330f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_bec30aea-a184-4302-a12a-84f2400ef0fb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3789ce0d-00ad-45ee-be67-9f8cff63fe46" xlink:to="loc_dei_EntityAddressAddressLine2_bec30aea-a184-4302-a12a-84f2400ef0fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_469b096a-70c2-412b-82d9-f6ae98b0a555" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3789ce0d-00ad-45ee-be67-9f8cff63fe46" xlink:to="loc_dei_EntityAddressCityOrTown_469b096a-70c2-412b-82d9-f6ae98b0a555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_82f16d3a-05a8-424f-9d59-553266b4fac3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3789ce0d-00ad-45ee-be67-9f8cff63fe46" xlink:to="loc_dei_EntityAddressStateOrProvince_82f16d3a-05a8-424f-9d59-553266b4fac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_5a6de26a-8856-40d7-9e84-b975c41cb6cc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3789ce0d-00ad-45ee-be67-9f8cff63fe46" xlink:to="loc_dei_EntityAddressPostalZipCode_5a6de26a-8856-40d7-9e84-b975c41cb6cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_7073d7a5-7223-4fd8-a8ab-ded864e8ea2b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3789ce0d-00ad-45ee-be67-9f8cff63fe46" xlink:to="loc_dei_CityAreaCode_7073d7a5-7223-4fd8-a8ab-ded864e8ea2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_9ce27056-a345-41fe-aadd-33cd70014911" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3789ce0d-00ad-45ee-be67-9f8cff63fe46" xlink:to="loc_dei_LocalPhoneNumber_9ce27056-a345-41fe-aadd-33cd70014911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_81dc16f2-2915-4261-8f5f-90f81ae0aa61" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3789ce0d-00ad-45ee-be67-9f8cff63fe46" xlink:to="loc_dei_WrittenCommunications_81dc16f2-2915-4261-8f5f-90f81ae0aa61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_02c4dd4d-4f3d-4f77-9a53-d6fc0d1f2b7b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3789ce0d-00ad-45ee-be67-9f8cff63fe46" xlink:to="loc_dei_SolicitingMaterial_02c4dd4d-4f3d-4f77-9a53-d6fc0d1f2b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_54592de3-8924-4ccf-9277-29ac2cf6517f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3789ce0d-00ad-45ee-be67-9f8cff63fe46" xlink:to="loc_dei_PreCommencementTenderOffer_54592de3-8924-4ccf-9277-29ac2cf6517f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_a27cbd18-3287-41d3-83a5-9336c5c02948" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3789ce0d-00ad-45ee-be67-9f8cff63fe46" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_a27cbd18-3287-41d3-83a5-9336c5c02948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_79f8666f-f1a1-4fff-8542-5f4bc62345b3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3789ce0d-00ad-45ee-be67-9f8cff63fe46" xlink:to="loc_dei_Security12bTitle_79f8666f-f1a1-4fff-8542-5f4bc62345b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_e9a7090b-edc6-4f7e-8a36-f4e9b481a340" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3789ce0d-00ad-45ee-be67-9f8cff63fe46" xlink:to="loc_dei_TradingSymbol_e9a7090b-edc6-4f7e-8a36-f4e9b481a340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_59c3ce80-a150-44ca-adf9-87acffa7893b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3789ce0d-00ad-45ee-be67-9f8cff63fe46" xlink:to="loc_dei_SecurityExchangeName_59c3ce80-a150-44ca-adf9-87acffa7893b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_649a0eb3-9194-4010-a18c-8e1a24354cec" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3789ce0d-00ad-45ee-be67-9f8cff63fe46" xlink:to="loc_dei_EntityEmergingGrowthCompany_649a0eb3-9194-4010-a18c-8e1a24354cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_0473dcf7-5088-4634-aeff-57725af0d19c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3789ce0d-00ad-45ee-be67-9f8cff63fe46" xlink:to="loc_dei_EntityCentralIndexKey_0473dcf7-5088-4634-aeff-57725af0d19c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_b3c1f422-0a3d-4814-b968-53cf2d728c31" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3789ce0d-00ad-45ee-be67-9f8cff63fe46" xlink:to="loc_dei_AmendmentFlag_b3c1f422-0a3d-4814-b968-53cf2d728c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_40ba6952-0857-4c55-be66-6266544ba493" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3789ce0d-00ad-45ee-be67-9f8cff63fe46" xlink:to="loc_dei_EntityExTransitionPeriod_40ba6952-0857-4c55-be66-6266544ba493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>img96626370_0.jpg
<TEXT>
begin 644 img96626370_0.jpg
M_]C_X  02D9)1@ ! 0        #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  M )L# 2(  A$! Q$!_\0
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MV,]0&V#N/< QQRZL?S![9,3<<;?P[EP/@<#C<//"*-'ZKOB!-1#52]UK!O\
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M;7#Y"2K&O]$CJKJH?MF:4>@]GIRV@2$D[28H"*+0B[M914K=(?32ZQ*7Z<
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MA@ R503!@=]AP.! =\Y$1#8!\<5!,](9SG(YR.1[CYP&WL& P&WCA9B+UO\
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M8#(?J30'CO\ \M6&0$<><=O_ )P3"GU #DF1!Q$F T M,F$X=( %JTBX$P[
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M(/H<F*/=SI_\8'*-$0+@-4 %# #C!:LH<I2@ !C8H 'N ^.P#C*AZTJGG/\
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MUEVD4LZ,J*PK'AFTNE&!]8@(I$;D;B( 44>C)1),),;@.-PVP.,B/MG& ]A
M0]L<:]/V-XQYSC?SU9S^_GSGBI#E9&/N$&1-#N'F$4KQA@;'F", ?6KNNF#$
M71(]Z)'L?]=6G2%&4I;^G8NDJ'IN#I&EH-J1E#T]3D:RAH:.:D .E!I',4T6
MZ0&-DZQBD]1<_P#?+'44$3C;];VCMA<J5HR<K^@J2K*8MW-_F2AI.HH9E*OJ
M3G2F2'\6@'+@AE(YZ H(&!=N(""B*1L=293!DST__+?_ "VR 8[9[8#MD?Z8
MV]/&-_V\^XFS]VX^,^0V[;<1[WW%@[!C=N"=Q)X-M=G<"0;N^;/3?O\ OW_]
M_P ]=.XC]^<B'8P=Q W3C&,& =S!D \Y[<0HOARY]$6HRI5JSO)IOMK656N@
M$SRIU(U:&G9 P&ZC*23^!=QIY)8XCA1P_(X<J8*!EAV'B;P)^XY[>_?&/YAV
M_;QXQMCB),AG/@1#N&,@ [" AOD \8QL(#P44\L#[X99(GH^:-V1JXL$J18[
M<'IP2.02/H3S^_GU'VQ&EK3SIBAW4#8.T-#VLCI Y#2(4M$)MG\G@2F3+*3#
M@[F6D2$,7K(@Z?*-TU!,H1(IQ$1D*G]A<CD<=\YS^^?.??SQL!,@&_? [Y'W
M_</ _P"GCVXYEV#'L(_U'@7DDE<O*[2,W=W9F<_4M9_7I$WR22?6_P#?7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140592770055824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 09, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  09,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">RALLYBIO CORPORATION<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">85-1083789<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">234 Church Street,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 1020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New Haven,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">06510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">859-3820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RLYB<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001739410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MJ#(9BBJ6<%H@XLD@;6E6?;!/3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%
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M?^:+X3]>?P%02P$"% ,4    " !W0:E8!T%-8H$   "Q    $
M    @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( '=!J5BCHA>D
M[P   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+
M 0(4 Q0    ( '=!J5B97)PC$ 8  )PG   3              "  <T!  !X
M;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ =T&I6!S&IO5Z!   MA$
M !@              ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+
M 0(4 Q0    ( '=!J5B?H!OPL0(  .(,   -              "  ;X,  !X
M;"]S='EL97,N>&UL4$L! A0#%     @ =T&I6)>*NQS     $P(   L
M         ( !F@\  %]R96QS+RYR96QS4$L! A0#%     @ =T&I6*K$(A8S
M 0  (@(   \              ( !@Q   'AL+W=O<FMB;V]K+GAM;%!+ 0(4
M Q0    ( '=!J5@D'INBK0   /@!   :              "  >,1  !X;"]?
M<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( '=!J5AED'F2&0$
M ,\#   3              "  <@2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%
3!@     )  D /@(  !(4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="rlyb-20240509.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rallybio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="rlyb-20240509.htm">rlyb-20240509.htm</File>
    <File>rlyb-20240509.xsd</File>
    <File>rlyb-20240509_lab.xml</File>
    <File>rlyb-20240509_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "rlyb-20240509.htm": {
   "nsprefix": "rlyb",
   "nsuri": "http://rallybio.com/20240509",
   "dts": {
    "inline": {
     "local": [
      "rlyb-20240509.htm"
     ]
    },
    "schema": {
     "local": [
      "rlyb-20240509.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "rlyb-20240509_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rlyb-20240509_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2022": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 24
   },
   "report": {
    "R1": {
     "role": "http://rallybio.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rlyb-20240509.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rlyb-20240509.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "CityAreaCode",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentType",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "Security12bTitle",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "TradingSymbol",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://rallybio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001739410-24-000053-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001739410-24-000053-xbrl.zip
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MQV8!_6-;*U27(YA[MZ&L'0H6?P"C#L[NN8H6"Y(^IGKV@/ >1HB#*^:1#J(
M<D8CF>[>O,6,MS&G9I^YW]36(!T"^!H"!@8T[80CXC _O,$5PT)<2%+5/I$>
M]U&/\HAPS+_S8"5E2"(^B'U) Q;&D3\F$;B^46^LODP_"!U8O\0C3K<BQ70G
M(89V!*'!."OKA3YTCM\A(.0818AJKRSX7M;MPOV)2:N^M_1RI;J1T'NUHMNV
MM8G0^V:#!6N%L;Y"P]AX]&C)6!."?Q5<@BQ@Q"L.TKA/]&!*IEG,U</-QI+O
MC;,\LW91-$PI ].8)0T9SB0KM&,0U:)52I7 K20%S$W8,RND^:%-K(*A0\55
MHFGW)>^]QF#:;LM')_2Y"^L97'T&XX)1EH>%H_3ZA6-*%C)(Z7)7,LPB!<P]
M(QQS:3L3T2B">E8UWZ3CI4G'I6!H.3 =7F4,(J@2%[T>>@@/24GY]4L)D$=S
M9^CSH"TQBYYF[3G[J\E,4O=-:EZXU+2B*&9B+=FIO,G.7=DI,*VXYZXF.VG=
M1P81%T9)MQ1$G &<B5?*!/BUPT4IM4JSI%XJ4.2U.:4%6Z\:]D:\4@#K1GDC
M7JE9U@UKW<Z?>E! J7+I?J_[9:2SK+@CU<43E$ENM=LGKD^C: UM^3*VC58E
MA: X6I7MT1D/G-#?6VN3Z%41XSQ-#%9LP3)C :KRIL_AS52?KK/;F*K'U$Z0
M"#PE;_YPW:X1Y[M]Y,0$C4W+49(V@2E5W/X>#("@'1FZWP[(D IR3?V8D7\J
M%6^2(9Z [7]?(N<#//GC+4@JY(E\3U;#SM7;9W^^?Q&$?H+<OX>I;!8?Q?89
MRDS.4]Q.#4&U,I\58AF@>1J=D\:_R4<_=*@/",T'C$8^4_&-+<\267>?>TN[
M,JW 0Y#.B#,FKMJA@6%] Y7*5"[IK>T3'A$8(B!\'/D5N1+AC>PCUA_BE@J-
MB,=ZT(4ZI)&$6XW2@@-ATW-@!;+WR\]FN7*(>^H%^U!%7K-OH#=8JR&>\L M
MOL1OL!S-6O&,V>VVT968?C[3NK[;.V>G2^B]YF[T]WO.CSK"E(W^HQI\,QG[
M(J=9BGAZBX29JX\>LT>]14GJW2,;!R 1"P6-W]FB[(,8*0T#8A2$RB>,(Z9J
M 9W3C5"\/X4K/S&YV ')J?KRQ]BYNFP'622 N4&)8-<\@N] .&G@8OB7NBX>
MY<#*>#V*1X47)5N@WC*'M+!')P[IK+CI+X411]T)V9*CE@]?9F+=%[IYNZ!B
MPQ=4S%X4,@R3E:H)YE-,DKMS=<AT"*IO8_H)=0#-Q/+N)P_=-K+NE2>5R94G
M?3&%7U=,<P2CWS3: ^M2H_X-'4<X^\W>B[(D0V=+D:V69 -BZ89%VBR*?:ER
M'2] .Z410- QY,-$_31#4(=8L)+I?99I+58R%P'!8]7IJ>H#TJ:^/W9X"#.8
MG*<!6!3%H#4I*%!,\@2.9114-@T"T+&NRF(!>DR5KT@IA$H;M>G?L3K+2A+E
M#L 2W-F"F72IDP;(W7"2L#+?!8"87BP"'O6Q?X1!?>YP26Q;-U%Y*YC3C(7
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MEBC+KT2<R+$F/YQC#)2"R$,:%U%!,AHO0-8<A#A*9> D) :@4%(I\!.@!6\
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M?7<6<K3LA>>1.B 'Q$".G \%< 4UBJ2-;%WR>O53MLX,?.+@HT[1.VBT\_P
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M4$L! A0#%     @ =T&I6)^(=53\#@  I&@  !$              ( !
M ')L>6(M,C R-# U,#DN:'1M4$L! A0#%     @ =T&I6 ;I#LAL @  9 <
M !$              ( !*P\  ')L>6(M,C R-# U,#DN>'-D4$L! A0#%
M  @ =T&I6'Q\NG6A"@  F5L  !4              ( !QA$  ')L>6(M,C R
M-# U,#E?;&%B+GAM;%!+ 0(4 Q0    ( '=!J5B*(R(%"@<   <U   5
M          "  9H<  !R;'EB+3(P,C0P-3 Y7W!R92YX;6Q02P$"% ,4
M" !W0:E8YCM_M9T<  !*U   '@              @ '7(P  <FQY8BTR,#(T
K,#4P.7AE>#DY,7!R97-S<F4N:'1M4$L%!@     %  4 4 $  +!       $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>rlyb-20240509_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="rlyb-20240509.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739410</identifier>
        </entity>
        <period>
            <startDate>2024-05-09</startDate>
            <endDate>2024-05-09</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-23">0001739410</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-24">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-05-09</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">RALLYBIO CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-40693</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">85-1083789</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">234 Church Street,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-8">Suite 1020</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">New Haven,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-10">CT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">06510</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-12">203</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">859-3820</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-18">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-19">RLYB</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-20">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-21">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c-1" id="f-22">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
